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ABSTRACT 
Aims: This trial aims to determine the effects of resistant starch (RS) subtype 2 (RS2) on 
glycemic status, metabolic endotoxemia and markers of oxidative stress. Methods: A 
randomized, controlled, parallel-group clinical trial group of 56 females with type 2 diabetes 
mellitus (T2DM) was divided to 2 groups. The intervention group (n = 28) and control group 
(n = 28) received 10 g/day RS2 or placebo for 8 weeks, respectively. Fasting blood samples 
were taken to determine glycemic status, endotoxin, high sensitivity C-reactive protein (hs-
CRP), malondialdehyde (MDA), total antioxidant capacity (TAC), antioxidant enzymes 
concentrations as well as uric acid at baseline and after the intervention. Results: After 8 
weeks, RS2 caused a significant decrease in the levels of MDA (-34.10%), glycosylated 
hemoglobin (-9.40%), insulin (-29.36%), homeostasis model of insulin resistance (-32.85%) 
and endotoxin (-25.00%), a significant increase in TAC (18.10%) and glutathione peroxidase 
(11.60%) as compared with control. No significant changes were observed in fasting plasma 
glucose, quantitative insulin sensitivity check index, hs-CRP, superoxide dismutase, catalase 
and uric acid in the RS2 group as compared with the control group. Conclusion: 
Supplementation with RS2 may be improved glycemic status, endotoxemia and markers of 
oxidative stress in patients with T2DM. 
Keyword: Antioxidant; Endotoxemia; Insulin; Malondialdehde; Resistant starch; Type 2 
diabetes 
